Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 21, 2011; 17(31): 3567-3574
Published online Aug 21, 2011. doi: 10.3748/wjg.v17.i31.3567
Published online Aug 21, 2011. doi: 10.3748/wjg.v17.i31.3567
Figure 1 Cumulative probability of relevant recurrence (grade 3 or 4 of endoscopic and/or clinical recurrence) depending on preventive use of azathioprine and active smoking.
Reproduced from Cortés et al[45] with permission. AZA: Azathioprine.
Figure 2 Algorithm for patient in medically or surgically induced remission.
Low risk is defined as long-standing, short segment fibrostenotic disease without or with minimum active inflammation. TNF: Tumor necrosis factor.
Figure 3 Relapse (flare-up) risk during follow-up of Crohn’s disease in continuing smokers, ex-smokers (quitters) and patients who have never smoked.
The stated P-value corresponds to comparison between the quitters and continuing smokers. Reproduced from Cosnes et al[18] with permission.
- Citation: Nos P, Domènech E. Management of Crohn’s disease in smokers: Is an alternative approach necessary? World J Gastroenterol 2011; 17(31): 3567-3574
- URL: https://www.wjgnet.com/1007-9327/full/v17/i31/3567.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i31.3567